Novartis gains EU nod for vaccine hopeful Bexsero

Novartis ($NVS) nabbed European approval for its new meningitis B vaccine Bexsero, for use in patients 2 months of age and older. The Swiss drugmaker says it's launching the shot as soon as possible across the continent, but country-by-country hurdles remain. Bexsero is seen as Novartis' best hope for breathing new life into its lagging vaccines unit. Release | Report